Patients with higher PD-L1 expression (tumor proportion score >50%) and TMB (≥10 mutations per megabase) had a better clinical response to ICI therapy without significant additional toxicity (Hui et al., 2017; Osipov et al., 2020). The gene discussed is CD274; the disease is neoplasm.